Shockwave Medical plans to acquire Neovasc for up to $147m and help bring the Reducer angina device to the US market.
Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy
Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.
